$Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)$

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)

Background: Disease status before high-dose chemotherapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) is an important predictor of transplantation-related toxicity and event-free survival (EFS) for patients with relapsed or refractory Hodgk...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 1998-03, Vol.9 (3), p.289-295
Hauptverfasser:	Josting, A., Kátay, I., Rueffer, U., Winter, S., Tesch, H., Engert, A., Diehl, V., Wickramanayake, P. D.
Format:	Artikel
Sprache:	eng
Schlagworte:	ABMT Adult Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Marrow Transplantation Carmustine - administration & dosage Combined Modality Therapy Cyclophosphamide - administration & dosage Cytarabine - administration & dosage Dexa-BEAM regimen Dexamethasone - administration & dosage Disease-Free Survival Dose-Response Relationship, Drug Etoposide - administration & dosage Female Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation high-dose chemotherapy Hodgkin Disease - mortality Hodgkin Disease - pathology Hodgkin Disease - therapy Hodgkin's disease Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Melphalan - administration & dosage Middle Aged Neoplasm Recurrence, Local - therapy PBSCT Salvage Therapy Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!